NAD+ Research | European NAD+ Therapy Pioneers
GENERAL RESEARCH INTO THE EFFECTS OF SYSTEMIC LOW LEVEL LASER
Low-level laser therapy (LLLT) is scientifically well documented for many indications; there are more than 100 double-blind positive studies confirming the clinical effect of LLLT. More than 2500 research reports are published. In 2005, The Postgraduate Medical Journal (81:436-441) published a scientific review of 100 scientific studies from Eastern Europe on the use of blood irradiation in the treatment of. The study was conducted by T Moshkovsk and J Mayberry from The Leicester General Hospital in Leicester, UK. The study was published under the name “It Is Time To Test Low Level Laser Therapy In Great Britain”. The authors of the study have come to the following conclusion: “The ability to non-thermally and non-destructively change cell function is known as laser bio-stimulation and is the basis for the current use of lasers in a number of medical fields. The worldwide interest in LLLT is illustrated by its use in more than 85 institutions in over 37 countries. Since the first study was reported in 1967, some 2500 papers have been published in a range of journals worldwide and the value of LLLT is much better reported than many believe. Its scientific background is sound enough to say that it is both safe and effective.” T Moshkovska And J Mayberry, Postgraduate Medical Journal 2005; 81: 436-441 © 2005 Fellowship Of Postgraduate Medicine.
For More Information On The Scientific Research, Please Refer To The Book:
Michael Weber, Medical Low-Level-Therapy – Foundation And Clinical Applications, 2. Edition, 2015, ISLA Research Group Laser Therapy – Clinical Practice And Scientific Background By Jan Tuner And Lars Hode, Or Visit The Research Library On The Website Tina Karu, The Science Of Low-Power-Laser Therapy
NAD+ INTRAVENOUS INFUSIONS THERAPY
Nicotinamide adenine dinucleotide (NAD+) is a vitally important molecule found in all living cells. Its primary function was considered to be as a co-enzyme in the energy-harnessing processes within cells. Reduced levels of NAD+ will impact cellular repair processes, which could result in the development of disease and enhancement of the ageing process. Every time we breathe, it burns the fuel in our cells and turns it into energy. In turn, the energy runs through our cells to create millions of chemical reactions that are needed to be alive. This oxidative stress causes many diseases as well as the ageing process.
Excessive oxidative stress is a feature of conditions ranging from neurodegenerative disorders (Parkinson’s disease, Alzheimer’s disease, Motor Neuron Disease), acute neurological conditions (trauma, hypoxia, epilepsy), drug and alcohol addiction, presumed auto-immune disorders (Chronic Fatigue Syndrome, Lupus, Fibromyalgia, Multiple Sclerosis, Rheumatoid Arthritis), genetic diseases (Muscular Dystrophies, Mitochondrial diseases, Huntington’s Disease) and metabolic diseases (Diabetes type 2, respiratory and cardiovascular disease) as well as the ageing process itself.
HISTORY OF NAD+
The NAD+ coenzyme was first discovered by British biochemists Arthur Harden and William John Young in 1906. They found that adding boiled and filtered yeast extract accelerated alcoholic fermentation greatly in unboiled yeast extracts. They called the unidentified factor responsible for this effect a coferment.
Vitamin precursors of NAD+ were identified in 1938, when Conrad Elvehjem showed that the liver has an “anti-black tongue” activity in the form of nicotinamide.
Then, in 1939, the first strong evidence was found that niacin is used to synthesize NAD+. In the early 1940s, Arthur Kornberg made another important contribution towards understanding NAD+ metabolism by being the first to detect an enzyme in the biosynthetic pathway.
The metabolism of NAD+ has remained an area of intense research into the 21st century, with interest being heightened after the discovery of the NAD+-dependent protein deacetylases (called sirtuins) in 2000 by Shin-ichiro Imai and coworkers at the Massachusetts Institute of Technology.
NAD+ Cell Founder
For over a decade, he has travelled the world to obtain answers. This led to the realisation that the co-enzyme NAD+ (Nicotinamide adenine dinucleotide) was the central metabolite required for cell function.
NAD+ is a compound which is found in all living cells. This small molecule is a core essential for life. It plays many essential roles during the metabolic process, where it turns nutrients into energy.
Some of the conditions that could be treated with NAD+
- Chronic Fatigue Syndrome
- Lyme’s Disease
- Alcohol Detox
- Rheumatoid Arthritis
- General Fatigue And/Or Exhaustion
- Recovery After Illness
- Chronic Fatigue/MS
- Burnout Syndrome
- Cancer Fatigue
- Coronary Heart Disease
- Heart Failure
- Erectile Dysfunction
- Hay Fever
- Autoimmune Diseases
- Rheumatoid Arthritis
- Multiple Sclerosis
- Recurrent Infections
- Chronic Infections (Bacterial, Viral And Parasites)
- Chronic And Chronic Recurrent Chest Infections
- Influenza (Recovery)
- Lyme Disease
- Chronic Hepatitis
- Low Immunity
- Hashimoto Disease
- Multiple Sclerosis
- Chronic Head Ache
- Anxiety Disorder
- Stress-Related Conditions
- Irritable Bladder Syndrome
- Chronic Toxicity
- Hearing Loss
- Hormonal Imbalances
- Some Forms Of Infertility
- Macular Degeneration
- Performance Improvement (Sport)
- Chronic Kidney Disease, Incl. Renal Failure
- Chronic Rhinitis And Sinusitis
- Significant Improvement Of General Fitness
- Improved Sleep And Vigilance
- Improved Mood
- Reduced Drug Consumption
- Optimization Of Diabetic Metabolism
- Improved Blood Fat Profile
- Improved Liver And Kidney Function
- Reduction Of Relapse Of Chronic-Inflammatory Bowel Disease
- Improved General Wellbeing And Mobility In Multiple Sclerosis
- Improved Pain Control In Chronic Pain
- Improved Tinnitus
- Reduction Of Anti-Hypertensive Medication
- It Activates The Parasympathetic Activity Of The Autonomic Nervous System Counteracting The Long Term Effect Of Stress On The Organism.